NCT03886662 - A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

May 31, 2021

Study Completion Date

July 31, 2021

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

LB-100

"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."

Trial Locations (1)

33612

RECRUITING

H. Lee Moffitt Cancer Center & Research Institute, Tampa